Nothing Special   »   [go: up one dir, main page]

ES2616477T3 - Heterociclaminas como inhibidores de pi3k - Google Patents

Heterociclaminas como inhibidores de pi3k Download PDF

Info

Publication number
ES2616477T3
ES2616477T3 ES12775861.3T ES12775861T ES2616477T3 ES 2616477 T3 ES2616477 T3 ES 2616477T3 ES 12775861 T ES12775861 T ES 12775861T ES 2616477 T3 ES2616477 T3 ES 2616477T3
Authority
ES
Spain
Prior art keywords
alkyl
independently selected
alkynyl
alkenyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12775861.3T
Other languages
English (en)
Inventor
Yun-Long Li
Wenqing Yao
Andrew P. Combs
Eddy W. Yue
Song MEI
Wenyu Zhu
Joseph Glenn
Thomas P. Maduskuie, Jr.
Richard B. Sparks
Brent Douty
Chunhong He
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Holdings Corp
Original Assignee
Incyte Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Holdings Corp filed Critical Incyte Holdings Corp
Application granted granted Critical
Publication of ES2616477T3 publication Critical patent/ES2616477T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de Fórmula I: **Fórmula** o una sal farmacéuticamente aceptable del mismo, en donde: X es CR9 o N; W es CR7 o N; Y es CR8, CR8a, o N; Z es un enlace o C(>=O); siempre que -W>=Y-Z- es -CR7>=CR8, -N>=CR8-, -CR7>=CR8a -C(>=O)-, -N>=CR8a -C(>=O)-o -CR7>=NC(>=O)-; R1 es alquilo C1-3; R2 es halo, alquilo C1-6, alcoxi C1-6, haloalquilo C1-6, haloalcoxi C1-6, fenilo o heteroarilo de 5 a 6 miembros; donde dicho fenilo y heteroarilo de 5 a 6 miembros están cada uno opcionalmente sustituidos por 1, 2, 3, o 4 sustituyentes seleccionados independientemente de halo, OH, CN, alquilo C1-4, alcoxi C1-4, y haloalcoxi C1-4; R3 es Cy,-(alquileno C1-3)-cy, halo, CN, NO2, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6 ORa, SRa, C(>=O)Rb, C(>=O)NRcRd, C(>=O)ORa, OC(>=O)Rb, OC(>=O)NRcRd, NRcRd, NRcC(>=O)Rb, NRc>=C(>=O)ORb, NRcC(>=O)NRcRd, C(>=NRe)Rb, C(>=NRe) NRcRd, NRcC(>=NRe) NRcRd, NRcS(>=O)2Rb, NRcS(>=O)2NRcRd, S(>=O)2Rb, o S(>=O)2NRcRd; en el que dicho alquilo C1-6, alquenilo C2-6 y alquinilo C2-6 están cada uno opcionalmente sustituidos por 1, 2, 3, o 4 grupos independientemente seleccionados 43a; R4 es H, halógeno, OH, CN, alquilo C1-4, haloalquilo C1-4, alcoxi C1-4, o haloalcoxi C1-4; R5 es halo, OH, CN, alquilo C1-4, haloalquilo C1-4, alcoxi C1-4, haloalcoxi C1-4, o ciclopropilo; R6 es H, halo, OH, CN, alquilo C1-4, haloalquilo C1-4, alcoxi C1-4, o haloalcoxi C1-4; R7 es H o alquilo C1-4; R7 es H, halo, -OH, -CN, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, Cy2 ,-(alquileno C1-3)-Cy2, ORa2 SRa2, C(>=O)Rb2, C(>=O)NRc2Rd2, C(>=O)ORa2, OC(>=O)Rb2, OC(>=O)NRc2Rd2, NRc2Rd2, NRc2C(>=O)Rb2, NRc2C(>=O)ORb2, NRc2C(>=O)NRc2Rd2, C(>=NRe)Rb2, C(>=NRe) NRc2Rd2, NRc2C(>=NRe) NRc2Rd2, NRc2S(>=O)Rb2, NRc2S(>=O)2NRc2Rd2, S(>=O)Rb2, S(>=O)2Rb2, o S(>=O)2NRc2Rd2; en el que dicho alquilo C1-6, alquenilo C2-6, alquinilo C2-6 están cada uno opcionalmente sustituidos por 1, 2, 3, o 4 grupos seleccionados independientemente R11; R8a es H, halo, -CN, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, Cy2 ,-(alquileno C1-3)-Cy2, C(>=O)Rb2, C(>=O)NRc2Rd2, C(>=O)ORa2, NRc2Rd2, NRc2C(>=O)Rb2, NRc2C(>=O)ORb2, NRc2C(>=O)NRc2Rd2, NRc2S(>=O)Rb2, NRc2S(>=O)2NRc2Rd2, S(>=O)Rb2, S(>=O)2Rb2, o S(>=O)2NRc2Rd2; en el que dicho alquilo C1-6, alquenilo C2-6, alquinilo C2-6 están cada uno opcionalmente sustituidos por 1, 2, 3, o 4 grupos seleccionados independientemente R11; R7 es H, halógeno, OH, CN, alquilo C1-4, haloalquilo C1-4, alcoxi C1-4, o haloalcoxi C1-4; R10 es H o alquilo C1-4; cada Ra, Rb, Rc y Rd se selecciona independientemente de H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6 y Cy; en el que dicho alquilo C1-6, alquenilo C2-6 y alquinilo C2-6 están cada uno opcionalmente sustituidos por 1, 2 ó 3 grupos R3b seleccionados independientemente; o Rc y Rd junto con el átomo N al que están unidos forman un grupo de heterocicloalquilo de 4, 5, 6, o 7 miembros, el cual está opcionalmente sustituido por -OH o alquilo C1-3; cada Re se selecciona independientemente de H, CN, OH, alquilo C1-4, y alcoxi C1-4; cada Cy se selecciona independientemente de cicloalquilo C3-7, heterocicloalquilo de 4 a 10 miembros, fenilo, naftilo, y heteroarilo de 5 a 10 miembros, cada uno de los cuales está opcionalmente sustituido por 1, 2, 3, o 4 grupos R3b seleccionados independientemente; cada R3a se selecciona independientemente de halo, CN, NO2, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, ORa1, SRa1, C(>=O)Rb1, C(>=O)NRc1Rd1, C(>=O)ORa1, OC(>=O)Rb1, OC(>=O)NRc1Rd1, NRc1Rd1, NRc1C(>=O)Rb1, NRc1C(>=O)ORb1, NRc1C(>=O)NRc1Rd1, C(>=NRe)Rb1, C(>=NRe) NRc1Rd1, NRc1C(>=NRe), NRc1Rd1, NRc1S(>=O)Rb1, NRc1S(>=O)2NRc1Rd1, S(>=O)2Rb1, y S(>=O)2NRc1Rd1; en el que dicho alquilo C1-6, alquenilo C2-6, alquinilo C2-6 están cada uno opcionalmente sustituidos por 1, 2 ó 3 grupos R11 seleccionados independientemente; cada R3b se selecciona independientemente de Cy1 ,-(alquileno C1-3)-cy1, halo, CN, NO2, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, ORa1, SRa1, C(>=O)Rb1, C(>=O)NRc1Rd1, C(>=O)ORa1, OC(>=O)Rb1, OC(>=O)NRc1Rd1, NRc1Rd1, NRc1C(>=O)Rb1, NRc1C(>=O)ORb1, NRc1C(>=O)NRc1Rd1, C(>=NRe)Rb1, C(>=NRe) NRc1Rd1, NRc1C(>=NRe) NRc1Rd1, NRc1S(>=O)Rb1, NRc1S(>=O)2NRc1Rd1, S(>=O)Rb1, S(>=O)2Rb1, y S(>=O)2NRc1Rd1; en el que dicho alquilo C1-6, alquenilo C2-6, alquinilo C2-6 están cada uno opcionalmente sustituidos por 1, 2 ó 3 grupos R11 seleccionados independientemente; cada Cy1 se selecciona independientemente de cicloalquilo C3-7, heterocicloalquilo de 4 a 7 miembros, fenilo, y heteroarilo de 5 a 6 miembros, cada uno de los cuales está opcionalmente sustituido por 1, 2, 3, o 4 grupos R11 seleccionados independientemente ; cada Ra1, Rb1, Rc1, y Rd1 se selecciona independientemente de H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, heterocicloalquilo de 4 a 7 miembros, fenilo, y heteroarilo de 5 a 6 miembros; en el que dicho alquilo C1-6, alquenilo C2-6, alquinilo C2-6, Cicloalquilo C3-7, heterocicloalquilo de 4 a 7 miembros, fenilo y heteroarilo de 5 a 6 miembros están cada uno opcionalmente sustituidos por 1, 2 o 3 grupos R11 seleccionados independientemente; o Rc1y Rd1 junto con el átomo N al que están unidos forman un grupo de heterocicloalquilo de 4, 5, 6, 7 miembros, que está opcionalmente sustituido por -OH o alquilo C1-3; cada Cy2 se selecciona independientemente de cicloalquilo C3-7, heterocicloalquilo de 4 a 7 miembros, fenilo, heteroarilo de 5 a 6 miembros o heteroarilo bicíclico de 9 a 10 miembros, cada uno de los cuales está opcionalmente sustituido por 1, 2, 3, o 4 grupos R11 seleccionados independientemente; cada Ra2, Rb2, RC2, y Rd2 se selecciona independientemente de H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, Cicloalquilo C3-7, heterocicloalquilo de 4 a 7 miembros, fenilo, y heteroarilo de 5 a 6 miembros; en el que dicho alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, heterocicloalquilo de 4-7 miembros, fenilo y heteroarilo de 5 a 6 miembros están cada uno opcionalmente sustituidos por 1, 2 o 3 grupos R11 seleccionados independientemente; o Rc2 y Rd2 junto con el átomo N al que están unidos forman un grupo de heterocicloalquilo de 4, 5, 6, o 7 miembros, que está opcionalmente sustituido por -OH o alquilo C1-3; y cada R11 se selecciona independientemente de OH, NO2, CN, halo, alquilo C1-3, alquenilo C2-3, alquinilo C2-3, haloalquilo C1-3, ciano-alquilo C1-3, HO-alquilo C1-3, alcoxi C1-3-alquilo C1-3, cicloalquilo C3-7, alcoxi C1-3, haloalcoxi amino C1-3, alquilamino C1-3, di(alquilo C1-3)amino, tio, alquiltio C1-3, alquilsulfinilo C1-3, alquilsulfonilo C1-3, carbamilo, alquilcarbamilo C1-3, di(alquilo C1-3)carbamilo, carboxi, alquilcarbonilo C1-3, alcoxicarbonilo C1-4, alquilcarbonilamino C1-3, alquilsulfonilamino C1-3, aminosulfonilo, alquilaminosulfonilo C1-3, di(alquilo C1-3)aminosulfonilo, aminosulfonilamino, alquilaminosulfoniloamino C1-3, di(alquilo C1-3)aminosulfonilamino, aminocarbonilamino, alquilaminocarbonilamino C1-3, y di(alquilo C1-3)aminocarbonilamino; en el que los átomos y heteroátomos de un grupo de heterocicloalquilo de carbono que forman anillo pueden estar opcionalmente sustituidos con oxo o sulfido.
ES12775861.3T 2011-09-02 2012-08-31 Heterociclaminas como inhibidores de pi3k Active ES2616477T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161530866P 2011-09-02 2011-09-02
US201161530866P 2011-09-02
US201261594882P 2012-02-03 2012-02-03
US201261594882P 2012-02-03
US201261677445P 2012-07-30 2012-07-30
US201261677445P 2012-07-30
PCT/US2012/053398 WO2013033569A1 (en) 2011-09-02 2012-08-31 Heterocyclylamines as pi3k inhibitors

Publications (1)

Publication Number Publication Date
ES2616477T3 true ES2616477T3 (es) 2017-06-13

Family

ID=47071429

Family Applications (3)

Application Number Title Priority Date Filing Date
ES12775861.3T Active ES2616477T3 (es) 2011-09-02 2012-08-31 Heterociclaminas como inhibidores de pi3k
ES16199883T Active ES2722524T3 (es) 2011-09-02 2012-08-31 Heterociclaminas como inhibidores de pi3k
ES18215449T Active ES2873001T3 (es) 2011-09-02 2012-08-31 Heterociclaminas como inhibidores de PI3K

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES16199883T Active ES2722524T3 (es) 2011-09-02 2012-08-31 Heterociclaminas como inhibidores de pi3k
ES18215449T Active ES2873001T3 (es) 2011-09-02 2012-08-31 Heterociclaminas como inhibidores de PI3K

Country Status (38)

Country Link
US (9) US9199982B2 (es)
EP (4) EP3196202B1 (es)
JP (8) JP6067709B2 (es)
KR (7) KR101982475B1 (es)
CN (1) CN106986867B (es)
AR (1) AR087760A1 (es)
AU (5) AU2012301721B2 (es)
BR (2) BR122019020716B1 (es)
CA (1) CA2846652C (es)
CL (1) CL2014000517A1 (es)
CO (1) CO6910199A2 (es)
CR (2) CR20180293A (es)
CY (3) CY1118679T1 (es)
DK (3) DK2751109T3 (es)
EA (2) EA028890B1 (es)
EC (1) ECSP14013274A (es)
ES (3) ES2616477T3 (es)
HK (1) HK1199644A1 (es)
HR (3) HRP20170285T1 (es)
HU (3) HUE030869T2 (es)
IL (7) IL314671A (es)
LT (3) LT2751109T (es)
ME (2) ME03397B (es)
MX (2) MX360262B (es)
MY (1) MY179332A (es)
NZ (1) NZ769326A (es)
PE (2) PE20181272A1 (es)
PH (2) PH12017501766B1 (es)
PL (3) PL3196202T3 (es)
PT (3) PT2751109T (es)
RS (3) RS58817B1 (es)
SG (3) SG11201400232WA (es)
SI (3) SI2751109T1 (es)
SM (1) SMT201700111B (es)
TW (6) TWI619714B (es)
UA (1) UA121539C2 (es)
WO (1) WO2013033569A1 (es)
ZA (1) ZA201904877B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2448938B9 (en) 2009-06-29 2015-06-10 Incyte Corporation Pyrimidinones as pi3k inhibitors
US8759359B2 (en) * 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
US8680108B2 (en) 2009-12-18 2014-03-25 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
US9193721B2 (en) 2010-04-14 2015-11-24 Incyte Holdings Corporation Fused derivatives as PI3Kδ inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
CA2822070C (en) 2010-12-20 2019-09-17 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
SI2751109T1 (sl) 2011-09-02 2017-03-31 Incyte Holdings Corporation Heterociklilamini kot inhibitorji pi3k
AR090548A1 (es) * 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
TWI653041B (zh) 2012-06-04 2019-03-11 美商製藥有限責任公司 布魯頓氏酪胺酸激酶抑制劑之結晶形式
KR20150079745A (ko) 2012-11-08 2015-07-08 리젠 파마슈티컬스 소시에떼 아노님 Pde4 억제제 및 pi3 델타 또는 이중 pi3 델타-감마 키나아제 억제제를 함유하는 약제학적 조성물
US9278950B2 (en) 2013-01-14 2016-03-08 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
PE20151448A1 (es) 2013-01-15 2015-09-28 Incyte Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
TWI657090B (zh) * 2013-03-01 2019-04-21 英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途
CR20160135A (es) 2013-08-23 2016-08-05 Incyte Corp Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de cinasas pim
JP6200603B2 (ja) 2014-02-03 2017-09-20 クワドリガ バイオサイエンシーズ, インコーポレイテッド 化学療法剤としてのβ置換βアミノ酸および類似体
BR112016017993A2 (pt) 2014-02-03 2017-08-08 Quadriga Biosciences Inc Gama-aminoácidos beta-substituídos e análogos como agentes quimioterapêuticos
SG11201608434TA (en) * 2014-04-08 2016-11-29 Incyte Corp Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
MY187502A (en) 2015-02-27 2021-09-24 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
EP3269367B1 (en) * 2015-03-11 2020-10-07 Riken Therapeutic agent for intractable leukemia
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AU2016302243B2 (en) 2015-08-03 2019-07-11 Quadriga Biosciences, Inc. Beta-substituted Beta-amino acids and analogs as chemotherapeutic agents and uses thereof
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
HRP20220599T1 (hr) 2015-11-06 2022-06-24 Incyte Corporation Heterociklički spojevi kao inhibitori pi3k-gama
TW201734003A (zh) 2016-01-05 2017-10-01 英塞特公司 作為PI3K-γ抑制劑之吡啶及嘧啶化合物
MY202022A (en) 2016-03-28 2024-03-29 Incyte Corp Pyrrolotriazine compounds as tam inhibitors
AR108875A1 (es) 2016-06-24 2018-10-03 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
PT3687996T (pt) 2017-09-27 2022-01-21 Incyte Corp Sais de derivados de pirrolotriazina úteis como inibidores de tam
JP7244504B2 (ja) 2017-10-18 2023-03-22 インサイト・コーポレイション PI3K-γ阻害剤としての三級ヒドロキシ基で置換された縮合イミダゾール誘導体
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
TWI827583B (zh) 2018-03-08 2024-01-01 美商英塞特公司 作為PI3K-γ抑制劑之胺基吡嗪二醇化合物
PE20211208A1 (es) 2018-06-01 2021-07-05 Incyte Corp Regimen de dosificacion para el tratamiento de trastornos relacionados con pi3k
AU2019293618A1 (en) 2018-06-29 2021-02-18 Incyte Corporation Formulations of an AXL/MER inhibitor
HUE066111T2 (hu) 2018-09-05 2024-07-28 Incyte Corp Foszfoinozitid-3-kináz (PI3K) gátló kristályos formái
US11396502B2 (en) 2018-11-13 2022-07-26 Incyte Corporation Substituted heterocyclic derivatives as PI3K inhibitors
US11078204B2 (en) 2018-11-13 2021-08-03 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
US11161838B2 (en) 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
TW202114681A (zh) 2019-07-02 2021-04-16 美商eFFECTOR醫療公司 轉譯抑制劑及其用途
US20210253582A1 (en) * 2020-02-06 2021-08-19 Incyte Corporation Salts and solid forms and processes of preparing a pi3k inhibitor
WO2022115120A1 (en) 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
WO2022115762A1 (en) 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
TW202329976A (zh) 2021-12-16 2023-08-01 美商英塞特公司 P13K—δ抑制劑之局部調配物
US11958832B1 (en) 2023-10-12 2024-04-16 King Faisal University 2-alkoxy[4,3:6,3-terpyridine]-3-carbonitriles as antimicrobial compounds

Family Cites Families (293)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3169967A (en) 1957-11-14 1965-02-16 Ciba Geigy Corp Methyl o-lower alkanoyl-reserpates
US3037980A (en) 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
DE1770420U (de) 1958-02-27 1958-07-17 Tara Union G M B H Blumentopf aus kunststoff.
US3506643A (en) 1966-12-09 1970-04-14 Max Thiel N**6-aralkyl-adenosine derivatives
DE2139107A1 (de) 1971-08-04 1973-02-15 Merck Patent Gmbh Heterocyclisch substituierte adenosinverbindungen
US3814251A (en) 1972-08-09 1974-06-04 Sperry Rand Corp Power transmission
US3962443A (en) 1972-08-14 1976-06-08 Dainippon Pharmaceutical Co., Ltd. Antibacterial pharmaceutical compositions and processes for preparation thereof
DE2248232A1 (de) 1972-10-02 1974-04-11 Basf Ag 4-thiopyrimido eckige klammer auf 4,5-d eckige klammer zu pyrimidine
AR204003A1 (es) 1973-04-03 1975-11-12 Dainippon Pharmaceutical Co Procedimiento para preparar compuestos derivados del acido 2-(1-piperazinil)-5-oxopirido-(2,3-d)pirimidino-6-carboxilico y sus sales farmaceuticamente aceptables
US3936454A (en) 1973-08-14 1976-02-03 Warner-Lambert Company 5-Amino-4-chloro-6-(substituted amino)-pyrimidines
US3862189A (en) 1973-08-14 1975-01-21 Warner Lambert Co Aralkyl-substituted purines and pyrimidines as antianginal bronchodilator agents
DK3375A (es) 1974-01-25 1975-09-15 Ciba Geigy Ag
JPS587626B2 (ja) 1974-02-13 1983-02-10 大日本製薬株式会社 ナフチリジン オヨビ キノリンユウドウタイノセイホウ
JPS50111080U (es) 1974-02-21 1975-09-10
JPS5625234Y2 (es) 1976-01-17 1981-06-15
JPS5359663A (en) 1976-11-09 1978-05-29 Sumitomo Chem Co Ltd 2-halogeno methyl indole derivatives and process for praparation of the same
JPS52106897A (en) 1977-01-10 1977-09-07 Dainippon Pharmaceut Co Ltd Synthesis of piperazine derivatives
JPS5392767A (en) 1977-01-27 1978-08-15 Sumitomo Chem Co Ltd Preparation of 2-phthalimidomethylindole derivatives
JPS5625234A (en) 1979-08-02 1981-03-11 Hitachi Denshi Ltd Dropout display system
JPS56123981U (es) 1980-02-20 1981-09-21
JPS56123981A (en) 1981-02-23 1981-09-29 Dainippon Pharmaceut Co Ltd Preparation of 1,4-disubstituted piperazine
JPS5883698A (ja) 1981-11-13 1983-05-19 Takeda Chem Ind Ltd キノン化合物およびその製造法
JPS5883698U (ja) 1981-11-27 1983-06-06 石川島播磨重工業株式会社 熱交換器
JPS58162949A (ja) 1982-03-20 1983-09-27 Konishiroku Photo Ind Co Ltd ハロゲン化銀カラ−写真感光材料
JPS60140373U (ja) 1984-02-28 1985-09-17 東洋ハ−ネス株式会社 ワイヤハ−ネスのア−ス構造
JPS6190153A (ja) 1984-10-09 1986-05-08 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料の処理方法
JPS62103640A (ja) 1985-07-18 1987-05-14 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料
JPS62103640U (es) 1985-12-18 1987-07-02
JPH07119970B2 (ja) 1986-04-18 1995-12-20 富士写真フイルム株式会社 画像形成方法
JPS6310746A (ja) 1986-07-01 1988-01-18 Tanabe Seiyaku Co Ltd ナフタレン誘導体
CA1324609C (en) 1986-07-30 1993-11-23 Eastman Kodak Company Photographic element and process
US4861701A (en) 1987-10-05 1989-08-29 Eastman Kodak Company Photographic element and process comprising a compound which comprises two timing groups in sequence
AT388372B (de) 1987-10-08 1989-06-12 Tanabe Seiyaku Co Neue naphthalinderivate und sie enthaltende pharmazeutika
JPH01250316A (ja) 1987-12-28 1989-10-05 Tanabe Seiyaku Co Ltd 抗脂血剤
EP0364598A4 (en) 1988-03-02 1992-01-15 Yoshitomi Pharmaceutical Industries, Ltd. 3,4-dihydrothieno 2,3-d¨pyrimidine compounds and pharmaceutical application thereof
US5208250A (en) 1988-05-25 1993-05-04 Warner-Lambert Company Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents
DE69132329T2 (de) 1990-04-25 2000-11-30 Nissan Chemical Industries, Ltd. Pyridazinonderivat
SU1712359A1 (ru) 1990-05-07 1992-02-15 Уфимский Нефтяной Институт Гидрохлорид 8 @ -гидроксихинолинового эфира 8-гидроксихинолин-7-карбоновой кислоты, в качестве бактерицида дл подавлени сульфатвосстанавливающих бактерий и культур РSеUDомоNаS и АRтнRовастеR
DE69129389T2 (de) 1990-06-28 1998-10-08 Fuji Photo Film Co Ltd Photographische Silberhalogenidmaterialien
EP0481614A1 (en) 1990-10-01 1992-04-22 Merck & Co. Inc. Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists
JPH04190232A (ja) 1990-11-26 1992-07-08 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU1625192A (en) 1991-05-31 1992-12-03 Zeneca Limited Heterocyclic derivatives
JP3108483B2 (ja) 1991-09-30 2000-11-13 日清製粉株式会社 インドール誘導体およびこれを有効成分とする抗潰瘍薬
HUT64064A (en) 1992-02-13 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing puyrido/1,2-a/pyrimidine derivatives and pharmaceutical compositions comprising same as active ingredient
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
WO1993022291A1 (en) 1992-04-24 1993-11-11 E.I. Du Pont De Nemours And Company Arthropodicidal and fungicidal aminopyrimidines
TW229140B (es) 1992-06-05 1994-09-01 Shell Internat Res Schappej B V
FR2714907B1 (fr) 1994-01-07 1996-03-29 Union Pharma Scient Appl Nouveaux dérivés de l'Adénosine, leurs procédés de préparation, compositions pharmaceutiques les contenant.
US6342501B1 (en) 1994-02-25 2002-01-29 The Regents Of The University Of Michigan Pyrrolo[2,3-d] pyrimidines as antiviral agents
JPH0987282A (ja) 1995-09-21 1997-03-31 Kyowa Hakko Kogyo Co Ltd チアゾール誘導体
JPH09176162A (ja) 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物
JPH09176116A (ja) 1995-12-27 1997-07-08 Toray Ind Inc 複素環誘導体およびその医薬用途
JPH1025294A (ja) 1996-03-26 1998-01-27 Akira Matsuda 縮合ヘテロ環誘導体、その製造法及びそれを含有する悪性腫瘍治療剤
WO1997048697A1 (en) 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
JP4667543B2 (ja) 1996-07-03 2011-04-13 大日本住友製薬株式会社 新規プリン誘導体
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
JPH10231297A (ja) 1997-02-20 1998-09-02 Japan Energy Corp 新規なアデニン−1−n−オキシド誘導体およびその医薬用途
CA2309350C (en) 1997-11-12 2007-04-03 Mitsubishi Chemical Corporation Purine derivatives and medicaments comprising the same as active ingredient
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
EA200000868A1 (ru) 1998-02-25 2001-04-23 Дженетикс Инститьют, Инк. Ингибиторы фосфолипаз
CN1298404A (zh) 1998-02-25 2001-06-06 遗传研究所有限公司 磷脂酶a2的抑制剂
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
SK16352000A3 (sk) 1998-05-04 2002-07-02 Zentaris Ag Indolové deriváty, spôsob ich výroby, ich použitie na liečivá obsahujúce tieto zlúčeniny
WO1999061436A1 (fr) 1998-05-26 1999-12-02 Chugai Seiyaku Kabushiki Kaisha Derives d'indole heterocycliques et derives de mono ou de di-azaindole
JP3997651B2 (ja) 1998-06-24 2007-10-24 コニカミノルタホールディングス株式会社 新規色素及び画像記録材料及び感熱転写材料及びインクジェット記録液
CA2339961C (en) 1998-08-11 2009-01-20 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
IL141513A0 (en) 1998-08-25 2002-03-10 Uab Research Foundation Inhibitors of bacterial nad synthetase
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
DE60023268T2 (de) 1999-02-01 2006-06-01 CV Therapeutics, Inc., Palo Alto INHIBITEURS PURIQUES DE KINASE 2 DEPENDANTE DES CYCLINES et IkB-alpha
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
JP2000281654A (ja) 1999-03-26 2000-10-10 Tanabe Seiyaku Co Ltd イソキノリン誘導体
DE19932571A1 (de) 1999-07-13 2001-01-18 Clariant Gmbh Verfahren zur Herstellung von Biarylen unter Palladophosphacyclobutan-Katalyse
JP2001151771A (ja) 1999-09-10 2001-06-05 Kyowa Hakko Kogyo Co Ltd 含窒素芳香族複素環誘導体
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US6436965B1 (en) 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
EP1138328A1 (en) 2000-03-29 2001-10-04 Eli Lilly And Company Limited Naphthalene derivatives as CNS drugs
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
CN1331340A (zh) 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人拓扑异构酶12.1和编码这种多肽的多核苷酸
US6960591B2 (en) 2000-07-05 2005-11-01 Yamanouchi Pharmaceutical Co., Ltd. Propane-1,3-dione derivative
FR2814073B1 (fr) 2000-09-21 2005-06-24 Yang Ji Chemical Company Ltd Composition pharmaceutique antifongique et/ou antiparasitaire et nouveaux derives de l'indole a titre de principes actifs d'une telle composition
DOP2002000334A (es) 2001-02-14 2002-08-30 Warner Lambert Co Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz
SE0100568D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
CN1659143A (zh) 2001-03-01 2005-08-24 盐野义制药株式会社 具有hiv整合酶抑制活性的含氮杂芳基化合物
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
JP2004525150A (ja) 2001-03-30 2004-08-19 スミスクライン ビーチャム コーポレーション 治療用化合物としてのピラゾロピリジン類の使用
JP4237497B2 (ja) 2001-03-30 2009-03-11 スミスクライン ビーチャム コーポレーション ピラゾロピリジン類、その調製方法及びその治療用化合物としての使用
ATE296826T1 (de) 2001-04-27 2005-06-15 Smithkline Beecham Corp Pyrazolo(1,5)pyridinderivate
CZ294535B6 (cs) 2001-08-02 2005-01-12 Ústav Experimentální Botaniky Avčr Heterocyklické sloučeniny na bázi N6-substituovaného adeninu, způsoby jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
WO2003024967A2 (en) 2001-09-19 2003-03-27 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
US6900205B2 (en) 2001-09-26 2005-05-31 Bayer Pharmaceuticals Corporation 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders
JP4459619B2 (ja) 2001-10-02 2010-04-28 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 化合物
DK1441737T3 (da) 2001-10-30 2006-11-13 Novartis Ag Staurosporin-derivater som inhibitorer af FLT3-receptor-tyrosinkinase-aktivitet
JP4663233B2 (ja) 2001-11-09 2011-04-06 エンゾン,インコーポレーテッド ベンジル脱離系を利用する高分子チオール結合プロドラッグ
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
ATE372341T1 (de) 2001-12-06 2007-09-15 Merck & Co Inc Inhibitoren von mitotischem kinesin
ATE424388T1 (de) 2001-12-06 2009-03-15 Merck & Co Inc Mitotische kinesinhemmer
TW200301135A (en) 2001-12-27 2003-07-01 Otsuka Maryland Res Inst Inc Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor
CA2476162A1 (en) 2002-02-13 2003-08-21 Takeda Chemical Industries, Ltd. Jnk inhibitor
WO2003074497A1 (en) 2002-03-01 2003-09-12 Pintex Pharmaceutical, Inc. Pin1-modulating compounds and methods of use thereof
EP1490371B1 (en) 2002-04-03 2007-08-15 Bristol-Myers Squibb Company Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same
KR20050006221A (ko) 2002-05-06 2005-01-15 제네랩스 테크놀로지스, 인코포레이티드 C형 간염 바이러스 감염 치료용의 뉴클레오시드 유도체
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
DE60322920D1 (de) 2002-08-13 2008-09-25 Shionogi & Co Heterocyclische verbindungen mit hiv-integrase-hemmender wirkung
JP4190232B2 (ja) 2002-08-26 2008-12-03 富士通株式会社 機械研磨を行う方法
TWI349671B (en) 2002-09-27 2011-10-01 Dainippon Sumitomo Pharma Co Novel adenine derivative and its use
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
ES2412273T3 (es) 2002-11-21 2013-07-10 Novartis Ag Inhibidores de 2-morfolín-4-pirimidinas como inhibidores de fosfotidilinositol (PI) 3-quinasa y su uso en el tratamiento del cáncer.
US7494987B2 (en) 2002-11-25 2009-02-24 Mochida Pharmaceutical Co., Ltd. Agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2004058682A1 (ja) 2002-12-26 2004-07-15 Eisai Co., Ltd. 選択的エストロゲン受容体モジュレーター
CZ294538B6 (cs) 2002-12-30 2005-01-12 Ústav Experimentální Botaniky Akademie Vědčeské Re Substituční deriváty N6-benzyladenosinu, způsob jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující
RU2233842C1 (ru) 2003-01-13 2004-08-10 Петров Владимир Иванович Производные пурина, обладающие противовирусной активностью
AR043692A1 (es) 2003-02-06 2005-08-10 Novartis Ag 2-cianopirrolopirimidinas y sus usos farmaceuticos
GB0304640D0 (en) 2003-02-28 2003-04-02 Novartis Ag Organic compounds
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
SE0300908D0 (sv) 2003-03-31 2003-03-31 Astrazeneca Ab Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
CA2524376A1 (en) 2003-05-05 2004-12-16 Neurogen Corporation Substituted imidazolopyrazine and triazolopyrazyne derivatives: gabaa receptor ligands
CN1809563A (zh) 2003-06-20 2006-07-26 希龙公司 吡啶并[1,2-a]嘧啶-4-酮化合物用作抗癌药
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
JP4570015B2 (ja) 2003-07-14 2010-10-27 クミアイ化学工業株式会社 2−イソオキサゾリン誘導体及びそれを有効成分として含有する除草剤
US20050124637A1 (en) 2003-08-15 2005-06-09 Irm Llc Compounds and compositions as inhibitors of receptor tyrosine kinase activity
AU2004274507B2 (en) 2003-09-18 2010-08-19 Conforma Therapeutics Corporation Novel heterocyclic compounds as HSP90-inhibitors
CA2539853C (en) 2003-09-23 2011-04-19 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
JP2007520559A (ja) 2004-02-03 2007-07-26 アボット・ラボラトリーズ 治療薬としてのアミノベンゾオキサゾール類
WO2005077948A1 (ja) 2004-02-16 2005-08-25 Daiichi Pharmaceutical Co., Ltd. 抗真菌作用複素環化合物
WO2005091857A2 (en) 2004-03-12 2005-10-06 Bayer Pharmaceuticals Corporation 1,6-naphthyridine and 1,8-naphthyridine derivatives and their use to treat diabetes and related disorders
CN1560035A (zh) 2004-03-12 2005-01-05 沈阳药科大学 5-羟基吲哚-3-羧酸脂类衍生物
US20070225303A1 (en) 2004-03-26 2007-09-27 Haruhisa Ogita 8-Oxoadenine Compound
US7217702B2 (en) 2004-04-02 2007-05-15 Adenosine Therapeutics, Llc Selective antagonists of A2A adenosine receptors
CA2566609C (en) 2004-05-13 2012-06-26 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
EP1753428A4 (en) 2004-05-14 2010-09-15 Abbott Lab INHIBITORS OF KINASES AS THERAPEUTIC AGENTS
UA84954C2 (ru) 2004-07-22 2008-12-10 Astrazeneca Ab Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования
AU2005273705B8 (en) 2004-08-18 2010-01-28 Astrazeneca Ab Enantiomers of selected fused pyrimidones and uses in the treatment and prevention of cancer
DE102004044221A1 (de) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
CA2584979A1 (en) 2004-10-19 2006-05-11 Novartis Vaccines And Diagnostics, Inc. Indole and benzimidazole derivatives
WO2006052546A2 (en) 2004-11-04 2006-05-18 Neurogen Corporation Pyrazolylmethyl heteroaryl derivatives
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
BRPI0517887A (pt) 2004-11-24 2008-10-21 Novartis Ag combinações de inibidores de jaks
AU2006214190A1 (en) 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
AU2006261715A1 (en) 2005-06-27 2007-01-04 Amgen Inc. Anti-inflammatory aryl nitrile compounds
FR2889192A1 (fr) 2005-07-27 2007-02-02 Cytomics Systems Sa Composes antifongiques, compositions contenant ces composes et leurs utilisations
MX2008002214A (es) 2005-08-16 2008-11-27 Genzyme Corp Compuestos de unión del receptor de quimiocina.
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
WO2007034817A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
GB0520657D0 (en) * 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
BRPI0618179A2 (pt) 2005-11-01 2011-08-23 Targegen Inc inibidores de biaril meta pirimidina de cinases
EP1783114A1 (en) 2005-11-03 2007-05-09 Novartis AG N-(hetero)aryl indole derivatives as pesticides
DE602006018057D1 (de) 2005-11-10 2010-12-16 Chemocentryx Inc Substituierte chinolone und verwendungsverfahren
ES2611588T3 (es) 2005-12-13 2017-05-09 Incyte Holdings Corporation Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
US20100227880A1 (en) 2006-01-25 2010-09-09 Kristjan Gudmundsson Chemical compounds
UY30118A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compueto amina trisustituido
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
EP1997804A1 (en) 2006-03-03 2008-12-03 Shionogi & Co., Ltd. Mmp-13-selective inhibitor
CA2647543A1 (en) 2006-03-29 2007-11-08 Foldrx Pharmaceuticals, Inc. Inhibition of alpha-synuclein toxicity
KR20090017498A (ko) * 2006-04-04 2009-02-18 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 Pi3 키나제 길항물질
DE102006029074A1 (de) * 2006-06-22 2007-12-27 Friedrich-Schiller-Universität Jena 4-Amino-3-arylamino-6-arylpyrazolo[3,4-d]pyrimidin-Derivate, Verfahren zu ihrer Herstellung und deren Verwendung als antivirale Wirkstoffe
US8933130B2 (en) 2006-06-23 2015-01-13 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
EP2044086A2 (en) 2006-06-30 2009-04-08 Janssen Pharmaceutica N.V. Thiazolopyrimidine modulators of trpv1
US20080009508A1 (en) 2006-07-10 2008-01-10 Lucie Szucova 6,9-Disubstituted Purine Derivatives And Their Use For Treating Skin
AU2007272009A1 (en) 2006-07-12 2008-01-17 Syngenta Limited Triazolopyridine derivatives as herbicides
SI2050749T1 (en) 2006-08-08 2018-04-30 Chugai Seiyaku Kabushiki Kaisha DERIVAT PYRIMIDINE AS A PI3K INHIBITOR AND ITS USE
MX2009002171A (es) 2006-08-30 2009-05-28 Cellzome Ltd Derivados de triazol como inhibidores de cinasas.
WO2008032033A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
EP1972631A1 (en) 2007-03-23 2008-09-24 Novartis AG Imidazopyridazines as PI3K lipid kinase inhibitors
US20080114007A1 (en) 2006-10-31 2008-05-15 Player Mark R 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
AU2007323836B2 (en) 2006-11-13 2013-04-18 Icos Corporation Thienopyrimidinones for treatment of inflammatory disorders and cancers
EP2099447B1 (en) 2006-11-22 2012-11-07 Incyte Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
CA2672960A1 (en) 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
MX2009006921A (es) 2006-12-29 2009-07-06 Hoffmann La Roche Derivados azaespiro.
WO2008097991A1 (en) 2007-02-05 2008-08-14 Xenon Pharmaceuticals Inc. Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions
US20090047246A1 (en) 2007-02-12 2009-02-19 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
PE20081887A1 (es) 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Nuevo compuesto de adenina
US20080233127A1 (en) 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
AU2008231304B2 (en) 2007-03-23 2011-05-12 Amgen Inc. Heterocyclic compounds and their uses
WO2008118454A2 (en) 2007-03-23 2008-10-02 Amgen Inc. Derivatives of quinoline or benzopyrazine and their uses for the treatment of (inter alia) inflammatory diseases, autoimmune diseases or various kinds of cancer
US8039505B2 (en) 2007-04-11 2011-10-18 University Of Utah Research Foundation Compounds for modulating T-cells
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US8088385B2 (en) 2007-06-18 2012-01-03 University Of Louisville Research Foundation Inc. PFKB3 inhibitor for the treatment of a proliferative cancer
AP2706A (en) 2007-06-29 2013-07-29 Gilead Sciences Inc Purine derivatives and their use as modulators of toll-like receptor 7
WO2009042294A2 (en) 2007-08-10 2009-04-02 Burnham Institute For Medical Research Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof
WO2009026701A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Sirtuin inhibitors
JP2009076865A (ja) 2007-08-29 2009-04-09 Fujifilm Corp 有機電界発光素子
WO2009034386A1 (en) 2007-09-13 2009-03-19 Astrazeneca Ab Derivatives of adenine and 8-aza-adenine and uses thereof-796
JP2009080233A (ja) 2007-09-26 2009-04-16 Kyocera Mita Corp 電子写真感光体
CZ300774B6 (cs) 2007-10-05 2009-08-05 Univerzita Palackého Substituované 6-(alkylbenzylamino)purinové deriváty pro použití jako antagonisté cytokininových receptoru a prípravky obsahující tyto slouceniny
EP2217239A2 (en) 2007-11-07 2010-08-18 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
WO2009063235A1 (en) 2007-11-13 2009-05-22 Astrazeneca Ab Derivatives of 1,9-dihydro-6h-purin-6-one and uses thereof-018
JP2009120686A (ja) 2007-11-14 2009-06-04 Toyo Ink Mfg Co Ltd 光重合開始剤、重合性組成物、および重合物の製造方法。
JP5520831B2 (ja) 2007-12-19 2014-06-11 アムジエン・インコーポレーテツド Pi3キナーゼの阻害薬
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009081105A2 (en) 2007-12-21 2009-07-02 Ucb Pharma S.A. Quinoxaline and quinoline derivatives as kinase inhibitors
JP2011507900A (ja) 2007-12-21 2011-03-10 ワイス・エルエルシー イミダゾ[1,2−a]ピリジン化合物
US7960397B2 (en) 2007-12-28 2011-06-14 Institute Of Experimental Botany, Academy Of Sciences Of The Czech Republic 6,9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions
US8410098B2 (en) 2007-12-28 2013-04-02 Topharman Shanghai Co., Ltd. N-{1-[3-(2-ethoxy-5-(4-ethylpiperazinyl)sulfonylphenyl)-4,5-dihydro-5-OXO-1,2,4-triazin-6-yl]ethyl}butyramide, the preparation method and use thereof
US8193182B2 (en) * 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2009098715A2 (en) 2008-01-11 2009-08-13 Natco Pharma Limited Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
US9089572B2 (en) 2008-01-17 2015-07-28 California Institute Of Technology Inhibitors of p97
US8987280B2 (en) 2008-01-30 2015-03-24 Genentech, Inc. Pyrazolopyrimidine PI3K inhibitor compounds and methods of use
WO2009128520A1 (ja) 2008-04-18 2009-10-22 塩野義製薬株式会社 P13k阻害活性を有する複素環化合物
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
WO2009140215A2 (en) 2008-05-11 2009-11-19 Geraghty, Erin Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds
US10301265B2 (en) 2008-05-28 2019-05-28 Virginia I. Roxas-Duncan Small molecule inhibitors of botulinum neurotoxins
CA2727174A1 (en) 2008-06-20 2010-01-21 Jiangao Song Aryl gpr119 agonists and uses thereof
US8026271B2 (en) 2008-07-11 2011-09-27 National Health Research Institutes Formulations of indol-3-yl-2-oxoacetamide compounds
WO2010018458A2 (en) 2008-08-12 2010-02-18 Crystalgenomics, Inc. Phenol derivatives and methods of use thereof
EP2346508B1 (en) 2008-09-26 2016-08-24 Intellikine, LLC Heterocyclic kinase inhibitors
US20100202963A1 (en) 2008-11-13 2010-08-12 Gallatin W Michael Therapies for hematologic malignancies
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US9353082B2 (en) 2008-12-24 2016-05-31 Bial—Portela & Ca, S.A. Pharmaceutical compounds
EP2387575B1 (en) 2009-01-15 2013-09-04 Anvyl, LLC Alpha7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof
ES2598358T3 (es) 2009-02-13 2017-01-27 Ucb Pharma, S.A. Derivados de quinolina como inhibidores de PI3K quinasa
TW201100428A (en) 2009-03-31 2011-01-01 Arqule Inc Substituted indolo-piperidine compounds
WO2010118367A2 (en) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
JP2012524126A (ja) 2009-04-20 2012-10-11 ギリアド カリストガ リミテッド ライアビリティ カンパニー 固形腫瘍の治療方法
WO2010127208A1 (en) 2009-04-30 2010-11-04 Forest Laboratories Holdings Limited Inhibitors of acetyl-coa carboxylase
CA2760791C (en) 2009-05-07 2017-06-20 Intellikine, Inc. Heterocyclic compounds and uses thereof
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
CA2765817A1 (en) 2009-06-25 2010-12-29 Amgen Inc. 4h-pyrido[1,2-a]pyrimidin-4-one derivatives as pi3k inhibitors
AU2010265974B2 (en) * 2009-06-25 2014-09-11 Amgen Inc. Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases
NZ622505A (en) 2009-06-29 2015-12-24 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
EP2448938B9 (en) 2009-06-29 2015-06-10 Incyte Corporation Pyrimidinones as pi3k inhibitors
EA201270184A1 (ru) 2009-07-21 2012-08-30 ГИЛИЭД КАЛИСТОГА ЭлЭлСи Лечение расстройств печени ингибиторами pi3k
PL2470546T3 (pl) 2009-08-28 2013-12-31 Takeda Pharmaceuticals Co Związki heksahydrooksazynopterydynowe do zastosowania jako inhibitory MTOR
WO2011028685A1 (en) 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TW201125867A (en) 2009-10-20 2011-08-01 Cellzome Ltd Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors
IN2012DN02984A (es) 2009-10-22 2015-07-31 Gilead Sciences Inc
BR112012010640A2 (pt) * 2009-11-05 2016-11-22 Rhizen Pharmaceuticals S A novos moduladores de quinase
MX2012005429A (es) 2009-11-10 2012-06-19 Pfizer Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa.
ES2534096T3 (es) 2009-11-12 2015-04-17 Ucb Pharma, S.A. Derivados de piridina y pirazina bicíclicos condensados como inhibidores de quinasa
WO2011058111A1 (en) 2009-11-12 2011-05-19 Ucb Pharma S.A. Aminopurine derivatives as kinase inhibitors
WO2011069294A1 (zh) 2009-12-10 2011-06-16 中国医学科学院药物研究所 N6-取代腺苷衍生物和n6-取代腺嘌呤衍生物及其用途
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
US8680108B2 (en) 2009-12-18 2014-03-25 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
AU2010330875B2 (en) 2009-12-18 2013-08-01 Amgen Inc. Heterocyclic compounds and their uses
CN102803248B (zh) * 2009-12-23 2015-09-16 梅迪奇制药有限公司 作为组胺h4受体拮抗剂的氨烷基嘧啶
JP2011136925A (ja) 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
RU2547721C2 (ru) 2010-01-07 2015-04-10 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи ТИАЗОЛО [5, 4-d] ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ АГРОХИМИЧЕСКИХ СРЕДСТВ
US8633183B2 (en) 2010-01-26 2014-01-21 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
HUE028723T2 (en) 2010-03-10 2016-12-28 Incyte Holdings Corp Piperidin-4-yl azetidine derivatives as JAK-1 inhibitors
CN102802632A (zh) 2010-03-22 2012-11-28 格兰马克药品股份有限公司 含有嘧啶酮衍生物的药物组合物
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
US9193721B2 (en) 2010-04-14 2015-11-24 Incyte Holdings Corporation Fused derivatives as PI3Kδ inhibitors
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
EP2579878A1 (en) 2010-06-11 2013-04-17 Gilead Calistoga LLC Methods of treating hematological disorders with quinazolinone compounds in selected patients
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
JP2013530238A (ja) 2010-07-01 2013-07-25 アムジエン・インコーポレーテツド Pi3k活性の阻害剤としての複素環化合物及びその使用
CA2803259A1 (en) 2010-07-01 2012-01-05 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
MX2012015134A (es) 2010-07-02 2013-05-06 Amgen Inc Compuestos heterociclicos y su uso como inhibidores de actividad de pi3k.
US20130324561A1 (en) 2010-09-24 2013-12-05 Gilead Calistroga Llc. Atropisomers of p13k-inhibiting compounds
CA2815445A1 (en) 2010-11-04 2012-05-10 Amgen Inc. 5 -cyano-4, 6 -diaminopyrimidine or 6 -aminopurine derivatives as pi3k-delta inhibitors
AU2011326427B2 (en) 2010-11-10 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
JP2013543000A (ja) 2010-11-17 2013-11-28 アムジエン・インコーポレーテツド 複素環化合物およびその使用
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
DK2835131T3 (en) 2010-12-14 2017-12-04 Electrophoretics Ltd Casein kinase 1 delta inhibitors (CK1 delta)
CA2822070C (en) 2010-12-20 2019-09-17 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US20130267526A1 (en) 2010-12-23 2013-10-10 Amgen, Inc. Heterocyclic compounds and their uses
EP3581574A1 (en) 2011-01-10 2019-12-18 Infinity Pharmaceuticals, Inc. A composition for oral administration for use in the treatment of cancer, an inflammatory disease or an auto-immune disease
USRE47009E1 (en) 2011-02-01 2018-08-28 The Children's Hospital Of Philadelphia HDAC inhibitors and therapeutic methods using the same
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
AU2012273164B2 (en) 2011-06-20 2015-05-28 Incyte Holdings Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
SI2751109T1 (sl) * 2011-09-02 2017-03-31 Incyte Holdings Corporation Heterociklilamini kot inhibitorji pi3k
JP2014528451A (ja) 2011-10-04 2014-10-27 ギリアード カリストガ エルエルシー Pi3kの新規キノキサリン阻害剤
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
AR093308A1 (es) 2012-11-01 2015-05-27 Incyte Corp Derivados triciclicos fusionados de tiofeno como inhibidores de jak
TWI657090B (zh) 2013-03-01 2019-04-21 英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途
KR102311329B1 (ko) 2013-03-15 2021-10-14 얀센 파마슈티카 엔.브이. 약제를 제조하기 위한 방법 및 중간체
KR102442747B1 (ko) 2013-05-17 2022-09-14 인사이트 코포레이션 Jak 저해제로서 비피라졸 유도체
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
AR103297A1 (es) 2014-12-30 2017-05-03 Forma Therapeutics Inc Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
MY187502A (en) 2015-02-27 2021-09-24 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183062A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
PE20211208A1 (es) 2018-06-01 2021-07-05 Incyte Corp Regimen de dosificacion para el tratamiento de trastornos relacionados con pi3k

Also Published As

Publication number Publication date
IL314671A (en) 2024-10-01
TW201313715A (zh) 2013-04-01
TW201917128A (zh) 2019-05-01
CR20180293A (es) 2018-09-19
AR087760A1 (es) 2014-04-16
PT2751109T (pt) 2017-03-06
TWI673272B (zh) 2019-10-01
CN104024253A (zh) 2014-09-03
NZ717505A (en) 2017-10-27
HRP20210627T1 (hr) 2021-05-28
US11819505B2 (en) 2023-11-21
ECSP14013274A (es) 2014-04-30
NZ621991A (en) 2016-07-29
TWI648277B (zh) 2019-01-21
JP2017052805A (ja) 2017-03-16
BR122019020716B1 (pt) 2021-02-17
NZ735378A (en) 2019-04-26
AU2021200266B2 (en) 2022-09-29
IL252184A0 (en) 2017-07-31
JP2017019851A (ja) 2017-01-26
CL2014000517A1 (es) 2014-08-22
BR112014004971B1 (pt) 2021-02-09
US20200323858A1 (en) 2020-10-15
ZA201904877B (en) 2022-11-30
EA028890B1 (ru) 2018-01-31
IL257576B (en) 2020-07-30
HRP20190824T1 (hr) 2019-07-12
US10646492B2 (en) 2020-05-12
JP6067709B2 (ja) 2017-01-25
PE20141726A1 (es) 2014-11-26
HUE043703T2 (hu) 2019-09-30
US20190134040A1 (en) 2019-05-09
PT3513793T (pt) 2021-05-10
CN106986867A (zh) 2017-07-28
IL299533A (en) 2023-02-01
EP2751109B1 (en) 2016-11-30
JP7384891B2 (ja) 2023-11-21
RS61761B1 (sr) 2021-05-31
JP2018044008A (ja) 2018-03-22
MX360262B (es) 2018-10-26
KR20190122801A (ko) 2019-10-30
TW201833115A (zh) 2018-09-16
NZ765458A (en) 2021-10-29
US20170340641A1 (en) 2017-11-30
DK3513793T3 (da) 2021-04-26
CY1124168T1 (el) 2022-05-27
KR20140082680A (ko) 2014-07-02
SG10201912484RA (en) 2020-02-27
KR20210054022A (ko) 2021-05-12
AU2021200266A1 (en) 2021-03-18
EP3888657A1 (en) 2021-10-06
US9707233B2 (en) 2017-07-18
KR20220035265A (ko) 2022-03-21
KR102249236B1 (ko) 2021-05-10
EA201791929A1 (ru) 2018-04-30
SG10201601589QA (en) 2016-04-28
TWI543980B (zh) 2016-08-01
PH12019502246A1 (en) 2021-02-22
CA2846652C (en) 2019-11-05
JP7038685B2 (ja) 2022-03-18
PH12017501766A1 (en) 2018-10-29
US11433071B2 (en) 2022-09-06
IL284539B2 (en) 2023-06-01
IL273079A (en) 2020-04-30
WO2013033569A1 (en) 2013-03-07
BR112014004971A2 (pt) 2017-03-21
PL3513793T3 (pl) 2021-09-20
SG11201400232WA (en) 2014-03-28
AU2022291574A1 (en) 2023-02-02
UA121539C2 (uk) 2020-06-25
JP6574039B2 (ja) 2019-09-11
ME02595B (me) 2017-06-20
JP2023184724A (ja) 2023-12-28
PT3196202T (pt) 2019-05-31
HK1199644A1 (en) 2015-07-10
DK3196202T3 (da) 2019-05-13
MY179332A (en) 2020-11-04
KR102030609B1 (ko) 2019-10-11
US20190298724A1 (en) 2019-10-03
IL231239A (en) 2017-05-29
EP3513793A1 (en) 2019-07-24
PE20181272A1 (es) 2018-08-03
JP2019011375A (ja) 2019-01-24
JP6263591B2 (ja) 2018-01-17
HRP20170285T1 (hr) 2017-04-21
EA033646B1 (ru) 2019-11-13
US10376513B2 (en) 2019-08-13
CY1121651T1 (el) 2020-07-31
PL3196202T3 (pl) 2019-09-30
JP2014527959A (ja) 2014-10-23
ES2722524T3 (es) 2019-08-13
CA2846652A1 (en) 2013-03-07
EP3196202B1 (en) 2019-02-27
NZ751428A (en) 2020-11-27
TW201942119A (zh) 2019-11-01
AU2012301721B2 (en) 2017-08-10
DK2751109T3 (en) 2017-01-23
SI3513793T1 (sl) 2021-07-30
EA201490541A1 (ru) 2014-08-29
SI2751109T1 (sl) 2017-03-31
NZ769326A (en) 2022-07-01
TWI765515B (zh) 2022-05-21
BR112014004971A8 (pt) 2019-11-05
US9730939B2 (en) 2017-08-15
PL2751109T3 (pl) 2017-06-30
KR102507287B1 (ko) 2023-03-07
MX2014002360A (es) 2014-04-25
LT3196202T (lt) 2019-07-10
IL273079B (en) 2021-07-29
PH12017501766B1 (en) 2018-10-29
RS55737B1 (sr) 2017-07-31
TW201639842A (zh) 2016-11-16
RS58817B1 (sr) 2019-07-31
CN106986867B (zh) 2019-06-28
AU2017206260A1 (en) 2017-08-10
SI3196202T1 (sl) 2019-05-31
JP2022034029A (ja) 2022-03-02
IL252184B (en) 2019-01-31
ME03397B (me) 2020-01-20
EP2751109A1 (en) 2014-07-09
SMT201700111B (it) 2017-03-08
LT2751109T (lt) 2017-02-27
CR20140111A (es) 2014-06-10
CO6910199A2 (es) 2014-03-31
KR20230038593A (ko) 2023-03-20
ES2873001T3 (es) 2021-11-03
KR101982475B1 (ko) 2019-05-27
KR20190045381A (ko) 2019-05-02
AU2017206260B2 (en) 2019-02-14
EP3513793B1 (en) 2021-03-10
AU2019201423B2 (en) 2020-10-22
HUE030869T2 (en) 2017-06-28
AU2012301721A1 (en) 2014-03-20
KR20200084905A (ko) 2020-07-13
TW202118765A (zh) 2021-05-16
JP2019194266A (ja) 2019-11-07
US20130059835A1 (en) 2013-03-07
EP3196202A1 (en) 2017-07-26
TWI717002B (zh) 2021-01-21
US20160022685A1 (en) 2016-01-28
US20240216377A1 (en) 2024-07-04
MX2020004502A (es) 2022-01-20
US10092570B2 (en) 2018-10-09
US20230121440A1 (en) 2023-04-20
CY1118679T1 (el) 2017-07-12
KR102131612B1 (ko) 2020-07-08
KR102371532B1 (ko) 2022-03-07
IL231239A0 (en) 2014-04-30
HUE053953T2 (hu) 2021-08-30
TWI619714B (zh) 2018-04-01
JP6427257B2 (ja) 2018-11-21
LT3513793T (lt) 2021-06-10
AU2019201423A1 (en) 2019-03-21
IL284539A (en) 2021-08-31
IL299533B1 (en) 2024-09-01
IL257576A (en) 2018-04-30
US9199982B2 (en) 2015-12-01
US20160024117A1 (en) 2016-01-28
JP6266743B2 (ja) 2018-01-24

Similar Documents

Publication Publication Date Title
ES2616477T3 (es) Heterociclaminas como inhibidores de pi3k
ES2569539T3 (es) Derivados de piperidin-4-il azetidina como inhibidores de JAK1
AR062240A1 (es) Derivados de [1,2,4]triazol[4,3-b][1,2,4]triazinas,composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer y otras enfermedades relacionadas con alteracion de quinasas.
AR081823A1 (es) DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
AR077280A1 (es) Pirimidinonas como inhibidores de pi3k, y composiciones farmaceuticas que los comprenden
AR064010A1 (es) Inhibidores de la actividad de la akt
AR080974A1 (es) Derivados piridinicos y piperazinicos moduladores de la actividad de los canales del calcio activado por depositos intracelulares(soc), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y trastornos inmunes, entre otras.
AR083296A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
AR087591A1 (es) Derivados de ciclohexil azetidina como inhibidores de jak
AR078408A1 (es) Derivados de indol como moduladores de los crac
CO6821946A2 (es) Derivados de piridin-2(1h)-ona útiles como medicamentos para el tramiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias
AR084507A1 (es) Derivados de indazoliltriazol
AR083933A1 (es) Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
AR078497A1 (es) Isoxazoles como antagonistas de los receptores de acido lisofosfatidico
AR070535A1 (es) Compuestos inhibidores de raf y metodos para usarlos
MX336224B (es) Quinolinas sustituidas y su uso como medicamentos.
AR086318A1 (es) Piridil aminopiridinas como inhibidores de syk
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
AR085316A1 (es) Derivados de pirrolo[2,3-b]piridina, utiles para la modulacion de quinasas
AR098549A1 (es) Derivados de amino pirimidina
AR086538A1 (es) COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE
AR090220A1 (es) Inhibidores de serina/treonina cinasa
RS52711B (en) INDOLAMIN 2,3-DIOXYGENASE MODULATORS AND PROCEDURES FOR USING THE SAME
AR089424A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
AR067413A1 (es) Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer